Eagle Asset Management Inc. Lowers Stock Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Eagle Asset Management Inc. reduced its position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 15.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 709,518 shares of the biotechnology company's stock after selling 132,053 shares during the quarter. Eagle Asset Management Inc. owned approximately 1.19% of Aldeyra Therapeutics worth $3,917,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of ALDX. US Bancorp DE bought a new stake in shares of Aldeyra Therapeutics in the 3rd quarter valued at $30,000. SG Americas Securities LLC acquired a new stake in shares of Aldeyra Therapeutics in the 2nd quarter valued at about $38,000. Diversified Trust Co bought a new stake in Aldeyra Therapeutics in the 2nd quarter valued at about $41,000. Laidlaw Wealth Management LLC boosted its holdings in Aldeyra Therapeutics by 32.6% in the second quarter. Laidlaw Wealth Management LLC now owns 16,875 shares of the biotechnology company's stock worth $56,000 after acquiring an additional 4,150 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Aldeyra Therapeutics by 14.4% during the second quarter. The Manufacturers Life Insurance Company now owns 21,734 shares of the biotechnology company's stock valued at $72,000 after acquiring an additional 2,729 shares in the last quarter. 59.71% of the stock is currently owned by institutional investors and hedge funds.

Aldeyra Therapeutics Stock Up 2.5 %

ALDX stock traded up $0.12 during trading on Monday, reaching $4.97. The stock had a trading volume of 584,100 shares, compared to its average volume of 500,052. Aldeyra Therapeutics, Inc has a one year low of $2.43 and a one year high of $6.55. The company's 50 day moving average is $5.32 and its two-hundred day moving average is $4.63. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.25). On average, analysts predict that Aldeyra Therapeutics, Inc will post -0.89 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Aldeyra Therapeutics in a research note on Friday, August 9th.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.